Nihal ŞAHİN, Sümeyra Özdemir ÇİÇEK, Ayşenur PAÇ KISAARSLAN, Zübeyde GÜNDÜZ, Muammer Hakan POYRAZOĞLU, Ruhan DÜŞÜNSEL

Unexpected condition in a rare disease: encephalopathy in early-onset sarcoidosis

Background. Granulomatous autoinflammatory diseases are monogenic syndromes caused by mutations in the region encoding the nucleotide-binding domain of the nucleotide-binding oligomerization domain-containing 2 gene. Blau syndrome and early-onset sarcoidosis are familial and sporadic forms of the same disease and are very rare. Many organ systems may be involved; however, neurologic involvement is infrequent. We reported a case of encephalitis in a 12-year-old girl followed with a diagnosis of early-onset sarcoidosis. Case. The patient was diagnosed with juvenile idiopathic arthritis at 3 years of age. We considered drug- induced sarcoidosis at 6 years of age with granulomatous inflammation of liver and kidney. Small joint involvement and camptodactyly developed during follow-up. M315T mutation was detected in the NOD2 gene supporting the diagnosis of early-onset sarcoidosis. The patient suffered from encephalopathy when she was under methotrexate, infliximab, and systemic steroid treatment at 12 years of age. Cerebrospinal fluid limbic encephalitis antibody panel was negative. Conclusion. Encephalopathy is not common in Blau syndrome and early-onset sarcoidosis. The cause of encephalopathy in our patient was interpreted as autoimmune encephalitis.

PDF

___

1. Blau EB. Familial granulomatous arthritis, iritis, and rash. J Pediatr 1985;107: 689-693.

2. Caso F, Rigante D, Vitale A, et al. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol 2013; 2013: 513782.

3. Caso F, Cantarini L, Lucherini OM, et al. Working the endless puzzle of hereditary autoinflammatory disorders. Mod Rheumatol 2014; 24: 381-389.

4. Caso F, Costa L, Rigante D, et al. Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmun Rev 2014; 13: 1220-1229.

5. Wouters CH, Maes A, Foley KP, Bertin J, Rose CD. Blau syndrome, the prototypic auto-inflammatory granulomatous disease. Pediatr Rheumatol Online J 2014; 12: 33.

6. Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol 2007; 26: 1969-1971.

7. Paç Kısaarslan A, Sözeri B, Şahin N, et al. Blau syndrome and early-onset sarcoidosis: a six case series and review of the literature. Arch Rheumatol 2020; 35: 117-127.

8. Villanueva-Mendoza C, Arellanes-Garca L, Cubas- Lorenzo V, Jimenez-Martinez MC, Flores-Surez LF, Zenteno JC. Familial case of Blau syndrome associated with a CARD15/NOD2 mutation. Ophthalmic Genet 2010; 31: 155-158.

9. Philpott DJ, Sorbara MT, Robertson SJ, Croitoru K, Girardin SE. NOD proteins: regulators of inflammation in health and disease. Nat Rev Immunol 2014; 14: 9-23.

10. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278: 8869-8872.

11. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Núñez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276: 4812-4818.

12. Inohara N, Nuñez G. NODS: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003; 3: 371-382.

13. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001; 411: 599-603.

14. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001; 411: 603-606.

15. Wang X, Kuivaniemi H, Bonavita G, et al. CARD15 mutations in familial granulomatosis syndromes: a study of the original Blau syndrome kindred and other families with large-vessel arteritis and cranial neuropathy. Arthritis Rheum 2002; 46: 3041-3045.

16. Parkhouse R, Boyle JP, Monie TP. Blau syndrome polymorphisms in NOD2 identify nucleotide hydrolysis and helical domain 1 as signalling regulators. FEBS Lett 2014; 588: 3382-3389.

17. Takeuchi Y, Shigemura T, Kobayashi N, et al. Early diagnosis of early-onset sarcoidosis: a case report with functional analysis and review of the literature. Clin Rheumatol 2017; 36: 1189-1196.

18. Kanazawa N, Okafuji I, Kambe N, et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 2005; 105: 1195- 1197.

19. Janssen CEI, Rose CD, De Hertogh G, et al. Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2-related disorders Blau syndrome and Crohn disease. J Allergy Clin Immunol 2012; 129: 1076-1084.

20. Rosé CD, Doyle TM, McIlvain-Simpson G, et al. Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. J Rheumatol 2005; 32: 373-375.

21. Okafuji I, Nishikomori R, Kanazawa N, et al. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. Arthritis Rheum 2009; 60: 242-250.

22. Tetsuka S, Ogawa T. Posterior reversible encephalopathy syndrome: a review with emphasis on neuroimaging characteristics. J Neurol Sci 2019; 404: 72-79.

23. Kidd DP. Neurosarcoidosis : clinical manifestations, investigation and treatment. Pract Neurol 2020; 20: 199-212.

24. Rosé CD, Aróstegui JI, Martin TM, et al. NOD2- associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain. Arthritis Rheum 2009; 60: 1797-1803.

25. Aróstegui JI, Arnal C, Merino R, et al. NOD2 gene- associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 2007; 56: 3805-3813.

26. Jabs DA, Houk JL, Bias WB, Arnett FC. Familial granulomatous synovitis, uveitis, and cranial neuropathies. Am J Med 1985; 78: 801-804.

27. Emaminia A, Nia AE, Nabavi M, Nasab MM, Kashef S. Central nervous system involvement in Blau syndrome: a new feature of the syndrome? J Rheumatol 2007; 34: 2504-2505.

28. Inoue Y, Kawaguchi Y, Shimojo N, et al. A case of infantile Takayasu arteritis with a p.D382E NOD2 mutation: an unusual phenotype of Blau syndrome/ early-onset sarcoidosis? Mod Rheumatol 2013; 23: 837-839.

29. Baykan B, Gungor Tuncer O, Vanli-Yavuz EN, et al. Delta brush pattern is not unique to NMDAR encephalitis: evaluation of two independent long- term EEG cohorts. Clin EEG Neurosci 2018; 49: 278- 284.

30. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391-404.

31. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307: 731-734.

32. Shaw PJ, Barr MJ, Lukens JR, et al. Signaling via the RIP2 adaptor protein in central nervous system- infiltrating dendritic cells promotes inflammation and autoimmunity. Immunity 2011; 34: 75-84.